Long-Term Efficacy and Safety Outcomes for Cardiac Myosin Inhibition in Adults With Symptomatic NYHA Class II–III Obstructive HCM

Join this interactive session to learn about cardiac myosin inhibition—its mechanism of action, pivotal study data, and long-term outcomes in adult patients with symptomatic NYHA Class II–III obstructive HCM.

Sponsored by Bristol Myers Squibb